G. Rajoria

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer

E. Antonarakis, K. Boucher, T. Lotan, 2018, Prostate Cancer and Prostatic Diseases.

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer

W. Isaacs, A. D. De Marzo, K. Yousefi, 2017, Clinical Cancer Research.

Factor V Leiden mutation is not increased in patients with inflammatory bowel disease.

M. Sabbath‐Solitare, N. Zauber, G. Mogan, 1998, Journal of clinical gastroenterology.

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer

E. Antonarakis, K. Boucher, T. Lotan, 2018, Prostate Cancer and Prostatic Diseases.